LHA - Investor Relations

Learn how #COCP is advancing clinical programs for norovirus, influenza A, and coronaviruses with novel, direct-acting candidates designed to inhibit viral replication. Explore promising compounds CDI-988 and CC-42344, along with insights into future prospects.

On-Demand Webinar – Explore innovative antiviral therapeutics from $COCP at the Life Sciences Investor Forum, co-hosted by Zacks Small Cap Research. virtualinvestorconferences.com/wcc/eh/4814904… #COCP #Biotech #Pharma #Antiviral #Influenza #Norovirus #ClinicalTrials #PharmaInnovation

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 nasdaq.com/press-release/… #COCP #Cocrystal #Nasdaq #pharma

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts #Cocrystal #Pharma #COCP #Viral globenewswire.com/news-release/2…

There is an “urgent unmet need for improved ovarian cancer treatments,” Premal Thaker Could IMUNON make a difference? Find out 9/18/24 at 10:00 a.m. ET at $IMNN’s R&D Day webcast here: lnkd.in/eiDPx4d5 $IMNN #IMNN #IMUNON linkedin.com/posts/imunon_t…

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs #Cocrystal #COCP #Pharma #Antiviral globenewswire.com/news-release/2…

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor #Cocrystal #COCP #Pharma #Viral #Norovirus #Coronavirus globenewswire.com/news-release/2…

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows #COCP #Cocrystal #Pharma #Antiviral #Influenza cocrystalpharma.com/news/press-rel…

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs #COCP #Cocrystal #Pharma #Antiviral globenewswire.com/news-release/2…

Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza #COCP #Cocrystal #Antiviral #Pharma #Influenza globenewswire.com/news-release/2…

EXECUTIVE INTERVIEW - Cocrystal Pharma: Utilizing Structure-Based Technologies to Provide First- & Best-In-Class Antiviral Drugs to Address Critically Unmet Medical Needs #COCP #Cocrystal #Pharma #Antiviral #Drugs #Medical drug-dev.com/executive-inte…

The Matinas team looks forward to presenting at this year's @ASGCTherapy Annual Meeting, taking place May 7-11, 2024 in Baltimore, MD. For event details: bit.ly/3eiSkX8 $MTNB #ASGCT2024

Check out Cappuccino with Claudio Ronco: 366. Discovery and application of new selective cytopheretic device #ICU #SeaStar #Medical #cytopheretic #ClaudioRonco youtu.be/onRUqgYaRDA?si…

Check out Critical Care Time Podcast #20 CRRT w/ Dr. Kevin Chung of SeaStar Medical— Critical Care Time #ICU #SeaStar #Medical #CRRT criticalcaretime.com/episodes/crrt

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs #COCP #Cocrystal #Pharma #Antiviral globenewswire.com/news-release/2…

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A #COCP #Cocrystal #Pharma #Influenza #FDA globenewswire.com/news-release/2…

Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates #COCP #Cocrystal #Pharma #Antiviral globenewswire.com/news-release/2…

Novel Antiviral Drug Shows Promise Treating Norovirus with Dr. Sam Lee Cocrystal Pharma #Cocrystal #COCP #Pharma #Health #Antiviral #Norovirus empoweredpatientradio.com/novel-antivira… empoweredpatientradio.com/novel-antivira…

SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts #SeaStar #ICU #Pediatric #Medical investors.seastarmedical.com/news/news-deta…

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A #Cocrystal #COCP #Pharma #Influenza #Antiviral #Pandemic globenewswire.com/news-release/2…